Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the expansion of its orthopedic trauma product portfolio in 2024. The company has introduced several new system extensions and received FDA 510(k) clearance for its first suture-based product, the TENSOR™ Suture Button System. New launches include ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws.
Surgeons across the U.S. have been implementing these new implants with positive feedback. Dr. Asif Ilyas from Thomas Jefferson University Hospital praised the ANTHEM™ II Volar plates for their contour and customization options. The company's orthopedic trauma business is experiencing rapid growth, with these new technologies and the integration of PRECICE™ magnetically actuated limb-lengthening nail technologies expanding their capacity to service diverse patient needs.
Globus Medical, Inc. (NYSE: GMED), un'azienda leader nel settore delle soluzioni muscoloscheletriche, ha annunciato l'espansione della sua linea di prodotti per il trauma ortopedico nel 2024. L'azienda ha introdotto diverse nuove estensioni di sistema e ha ricevuto l'approvazione FDA 510(k) per il suo primo prodotto basato su sutura, il sistema TENSOR™ Suture Button. I nuovi lanci includono piastre volari ANTHEM™ II per radius distale, strumenti PRO per chiodo trocanterico AUTOBAHN™ e viti senza testa CAPTIVATE™ SOLA.
I chirurghi negli Stati Uniti stanno implementando questi nuovi impianti con feedback positivi. Il Dr. Asif Ilyas dell'ospedale Thomas Jefferson University ha lodato le piastre volari ANTHEM™ II per il loro profilo e le opzioni di personalizzazione. L'attività di trauma ortopedico dell'azienda sta vivendo una rapida crescita, con queste nuove tecnologie e l'integrazione delle tecnologie di allungamento degli arti magneticamente azionate PRECICE™, che ampliano la loro capacità di soddisfare le diverse esigenze dei pazienti.
Globus Medical, Inc. (NYSE: GMED), una empresa líder en soluciones musculoesqueléticas, ha anunciado la expansión de su cartera de productos de trauma ortopédico en 2024. La compañía ha introducido varias nuevas extensiones de sistema y ha recibido la aprobación FDA 510(k) para su primer producto basado en suturas, el sistema TENSOR™ Suture Button. Los nuevos lanzamientos incluyen placas volares ANTHEM™ II para radio distal, instrumentos PRO para clavo trocantérico AUTOBAHN™ y tornillos sin cabeza CAPTIVATE™ SOLA.
Los cirujanos de EE. UU. han estado implementando estos nuevos implantes con comentarios positivos. El Dr. Asif Ilyas del Hospital de la Universidad Thomas Jefferson elogió las placas volares ANTHEM™ II por su contorno y opciones de personalización. El negocio de trauma ortopédico de la empresa está experimentando un rápido crecimiento, con estas nuevas tecnologías y la integración de las tecnologías de clavos de alargamiento de extremidades accionados magnéticamente PRECICE™, ampliando su capacidad para atender diversas necesidades de los pacientes.
글로부스 메디컬 주식회사 (NYSE: GMED)는 2024년에 정형 외과 외상 제품 포트폴리오의 확장을 발표했습니다. 이 회사는 여러 새로운 시스템 확장을 도입했으며, 최초의 봉합 기반 제품인 TENSOR™ 봉합 버튼 시스템에 대해 FDA 510(k) 승인을 받았습니다. 새로운 출시에는 ANTHEM™ II 원위 요골 복내판, AUTOBAHN™ 대퇴부 못 PRO 기구 및 CAPTIVATE™ SOLA 헤드리스 나사가 포함됩니다.
미국 전역의 외과 의사들은 긍정적인 피드백과 함께 이러한 새로운 임플란트를 시행하고 있습니다. 토마스 제퍼슨 대학교 병원의 아시프 일리야스 박사는 ANTHEM™ II 복내판의 윤곽과 맞춤화 옵션을 칭찬했습니다. 회사의 정형 외상 사업은 이러한 새로운 기술과 PRECICE™ 자석 작동 하지관 절단 기술의 통합으로 다양한 환자 요구를 충족할 수 있는 능력이 확장되면서 빠른 성장을 경험하고 있습니다.
Globus Medical, Inc. (NYSE: GMED), une entreprise leader dans les solutions musculosquelettiques, a annoncé l'expansion de son portefeuille de produits de trauma orthopédique pour 2024. L'entreprise a introduit plusieurs nouvelles extensions de système et a reçu l'approbation FDA 510(k) pour son premier produit basé sur une suture, le système TENSOR™ Suture Button. Les nouveaux lancements incluent plaques volares ANTHEM™ II pour le radius distal, instruments PRO pour clou trochantérique AUTOBAHN™ et vis sans tête CAPTIVATE™ SOLA.
Les chirurgiens à travers les États-Unis mettent en œuvre ces nouveaux implants avec des retours positifs. Le Dr Asif Ilyas de l'hôpital de l'université Thomas Jefferson a salué les plaques volares ANTHEM™ II pour leur contour et leurs options de personnalisation. L'activité de traumatisme orthopédique de l'entreprise connaît une croissance rapide, avec ces nouvelles technologies et l'intégration des technologies de clou d'allongement de membre activées magnétiquement PRECICE™, élargissant leur capacité à répondre aux divers besoins des patients.
Globus Medical, Inc. (NYSE: GMED), ein führendes Unternehmen im Bereich muskuloskelettaler Lösungen, hat die Erweiterung seines Portfolios für orthopädische Trauma-Produkte für das Jahr 2024 angekündigt. Das Unternehmen hat mehrere neue Systemerweiterungen eingeführt und die FDA 510(k)-Zulassung für sein erstes nahtbasiertes Produkt, das TENSOR™ Suture Button System, erhalten. Zu den neuen Produkten gehören ANTHEM™ II distale Radius-Platten, AUTOBAHN™ Trochanter-Nagel PRO Instrumente und CAPTIVATE™ SOLA kopflose Schrauben.
Chirurgen in den USA setzen diese neuen Implantate mit positiven Rückmeldungen um. Dr. Asif Ilyas vom Thomas Jefferson University Hospital lobte die ANTHEM™ II Volarplatten für ihre Kontur und Anpassungsoptionen. Das Geschäft mit orthopädischem Trauma des Unternehmens verzeichnet ein schnelles Wachstum, wobei diese neuen Technologien und die Integration der PRECICE™ magnetisch betriebenen Verlängerungstechnologien ihre Fähigkeit erweitern, vielfältige Patientenbedürfnisse zu bedienen.
- Expansion of orthopedic trauma product portfolio with new system extensions
- FDA 510(k) clearance received for TENSOR™ Suture Button System
- Positive feedback from surgeons on new implants and instrument sets
- Rapid growth of Globus Medical's orthopedic trauma business
- None.
Insights
Globus Medical's launch of new orthopedic trauma solutions represents a significant expansion of their product portfolio. The introduction of the TENSOR™ Suture Button System, their first suture-based product, marks a strategic entry into a new segment. This diversification, along with next-generation systems like ANTHEM™ II, AUTOBAHN™ Trochanteric Nail PRO and CAPTIVATE™ SOLA, demonstrates the company's commitment to innovation and market growth.
The positive feedback from surgeons, particularly from respected institutions like Thomas Jefferson University Hospital, indicates strong initial market acceptance. This could translate to increased adoption rates and potential market share gains in the competitive orthopedic trauma space.
The integration of PRECICE™ limb-lengthening technologies further broadens Globus Medical's reach, potentially opening up new revenue streams. For investors, this expansion signals a robust growth strategy that could drive future earnings, especially if the company can capitalize on cross-selling opportunities within its expanded portfolio.
Globus Medical's strategic expansion in the orthopedic trauma market is a positive indicator for potential revenue growth. With a market cap of
The FDA clearance for the TENSOR™ Suture Button System opens up a new revenue stream, while the next-generation systems could drive upgrades and new sales. This diversification strategy may help mitigate risks associated with reliance on a product range.
Investors should monitor upcoming quarterly reports for signs of revenue acceleration from these new products. Key metrics to watch include:
- Adoption rates of new systems
- Gross margin impact from product mix changes
- R&D expenses as a percentage of revenue
If successful, this product expansion could lead to improved financial performance and potentially higher valuation multiples for GMED stock.
AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio.
Globus has introduced several new system extensions so far in 2024 and received 510(k) clearance from the U.S. Food and Drug Administration for its first suture-based product, TENSOR™ Suture Button System. Newly launched, next-generation systems include ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws.
“The addition of these products to our growing orthopedic trauma portfolio signifies our continued responsiveness and dedication to surgeons and patients,” said John Mulcahy, Chief Commercial Officer and President of Orthopedics.
Surgeons across the U.S. have been implementing these new implants and instrument sets into their practices with positive feedback. Dr. Asif Ilyas, at Thomas Jefferson University Hospital, was one of the first users of the new ANTHEM™ II Volar plates. “The contour of the ANTHEM™ II Volar Plates and comprehensive fixation options allow me to further customize my surgical plans and achieve an anatomic fit,” said Dr. Ilyas. “I am excited for the continued use of the ANTHEM™ Distal Radius system in my practice.”
Globus Medical’s orthopedic trauma business is rapidly growing. With these new technologies building out the product portfolio and the continued integration of the PRECICE™ magnetically actuated limb-lengthening nail technologies, there is more capacity to service a wide variety of patient needs with innovative solutions.
About TENSOR™ Suture Button System
The TENSOR™ Suture Button System is engineered to redefine suture management in the operating room. The system features a self-locking suture and an inserter with integrated tensioning handles, which provides a streamlined approach for tensioning through a single incision. TENSOR™ is compatible with ANTHEM™ Ankle and One-Third Tubular Plates, offering surgeons a complete ankle solution. The system also features a two-hole washer kit that can aid in the repair of isolated syndesmotic injuries.
About ANTHEM™ Distal Radius Fracture System
The ANTHEM™ Distal Radius Fracture System is a comprehensive fixation system designed to treat a wide variety of wrist fractures with anatomically contoured plates for intraoperative versatility. Market-leading polyaxial locking technology allows for ±20° of angulation (40° cone) in polyaxial volar, fragment specific, and diaphyseal metaphyseal plates. MonoAx™ locking technology enables a thin volar plate design to facilitate distal plate placement in the treatment of complex, intra-articular fractures. Innovative instruments allow for secure retraction and streamlined plate positioning, drilling, and screw insertion.
About AUTOBAHN™ Trochanteric Nail System
The AUTOBAHN™ Trochanteric Nailing System is designed to treat a variety of pertrochanteric femur fractures. The PRO Instrument Set and Distal Targeting System allow for an efficient and streamlined surgical workflow.
About CAPTIVATE SOLA Screw System
The CAPTIVATE™ SOLA Headless Compression Screw System offers a flexible and efficient solution to address fracture repair, bone reconstruction, osteotomy, and arthrodesis procedures through ample implant options and shared instruments for paired screw sizes. Screw diameters include 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.5, 6.5, and 7.5mm in lengths ranging from 10-140mm. All screws are available in stainless steel and titanium alloy, with options for short and long partial threads. Small and large modular graphic cases house all nine screw diameters and corresponding instrument modules.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, their businesses successfully and to achieve anticipated synergies, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Investor contact:
Brian Kearns
610-930-1800
investors@globusmedical.com
Media contact:
Moran Chavez
media@globusmedical.com
FAQ
What new products has Globus Medical (GMED) launched in 2024 for orthopedic trauma?
Has Globus Medical (GMED) received any FDA clearances for its orthopedic trauma products in 2024?
How are surgeons responding to Globus Medical's (GMED) new orthopedic trauma products?
What is the current state of Globus Medical's (GMED) orthopedic trauma business?
